Why the study?
Modern guideline-recommended treatments for acute coronary syndromes, including new antiplatelet agents and drug-eluting stents, are underutilized in real-world practice, and the reasons for this implementation gap are unclear.
Observational (n=1,967)
Yes
Real-world registry data from the Czech Republic shows significant underutilization of novel P2Y12 inhibitors and drug-eluting stents in ACS patients, primarily driven by physician inertia rather than economic factors.
Guideline implementation for ACS in daily practice warrants closer scrutiny; leaves open the extent of adherence and outcomes impact.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Widimský et al. (2017) conducted an observational in Acute coronary syndromes (n=1,967). Guideline-recommended antiplatelet therapy vs. Non-adherence to guidelines was evaluated on Prescription of clopidogrel at discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: